|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2002-1-16
|
|
pubmed:abstractText |
Urokinase-type plasminogen activator (uPA) and its inhibitor (PAI-1) play essential roles in tumor invasion and metastasis. High levels of both uPA and PAI-1 are associated with poor prognosis in breast cancer patients. To confirm the prognostic value of uPA and PAI-1 in primary breast cancer, we reanalyzed individual patient data provided by members of the European Organization for Research and Treatment of Cancer-Receptor and Biomarker Group (EORTC-RBG).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0027-8874
|
|
pubmed:author |
pubmed-author:BeexLouk V A MLV,
pubmed-author:BendahlPär-OlaPO,
pubmed-author:BlankensteinMarinus AMA,
pubmed-author:BorstnarSimonaS,
pubmed-author:BrünnerNilsN,
pubmed-author:BroëtPhilippeP,
pubmed-author:ChristensenIb JarleIJ,
pubmed-author:CuferTanjaT,
pubmed-author:DaverAlainA,
pubmed-author:DaxenbichlerGünterG,
pubmed-author:DuffyMichael JMJ,
pubmed-author:DugganCatherineC,
pubmed-author:Eppenberger-CastoriSerenellaS,
pubmed-author:EppenbergerUrsU,
pubmed-author:FernöMårtenM,
pubmed-author:FietsW EdwardWE,
pubmed-author:FoekensJohn AJA,
pubmed-author:HarbeckNadiaN,
pubmed-author:JänickeFritzF,
pubmed-author:KatesRonaldR,
pubmed-author:KlijnJan G MJG,
pubmed-author:KuengWillyW,
pubmed-author:LisboaBjörn WBW,
pubmed-author:LookMaxime PMP,
pubmed-author:MagdelenatHenriH,
pubmed-author:MandersPeggyP,
pubmed-author:MartinPierre-MariePM,
pubmed-author:Meijer-van GelderMarion EME,
pubmed-author:O'HigginsNiallN,
pubmed-author:PeyratJean-PhilippeJP,
pubmed-author:QuillienVéroniqueV,
pubmed-author:RicolleauGabrielG,
pubmed-author:RomainSylvieS,
pubmed-author:SchmittManfredM,
pubmed-author:SpyratosFrédériqueF,
pubmed-author:SweepC G J FredCG,
pubmed-author:ThomssenChristophC,
pubmed-author:UlmKurtK,
pubmed-author:WindbichlerGudrunG,
pubmed-author:van PuttenWim L JWL
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
16
|
|
pubmed:volume |
94
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
116-28
|
|
pubmed:dateRevised |
2008-11-21
|
|
pubmed:meshHeading |
pubmed-meshheading:11792750-Adult,
pubmed-meshheading:11792750-Aged,
pubmed-meshheading:11792750-Biological Markers,
pubmed-meshheading:11792750-Breast Neoplasms,
pubmed-meshheading:11792750-Female,
pubmed-meshheading:11792750-Humans,
pubmed-meshheading:11792750-Middle Aged,
pubmed-meshheading:11792750-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:11792750-Prognosis,
pubmed-meshheading:11792750-Proportional Hazards Models,
pubmed-meshheading:11792750-Survival Analysis,
pubmed-meshheading:11792750-Urokinase-Type Plasminogen Activator
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
|
|
pubmed:affiliation |
Department of Medical Oncology, University Hospital Rotterdam, The Netherlands. look@bidh.azr.nl
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Meta-Analysis
|
